Skip to main content

Table 3 Multivariable adjusted analysis of the association between hourly dexmedetomidine dose and noradrenaline equivalent to MAP ratio (NEq/MAP)

From: The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial

Effect Estimate Standard error p value
Dexmedetomidine, per μg/kg/h increase − 0.165 0.071 0.02
Age, per year increase − 0.003 0.003 0.38
Baseline log NEq/MAP, per unit increase 0.312 0.059 < 0.001
Location
 Switzerland − 0.672 0.101 < 0.001
 Australia 0   
No hydrocortisone 0.134 0.108 0.22
hydrocortisone 0   
No CRRT − 0.635 0.105 < 0.001
CRRT 0   
No liver cirrhosis − 1.371 0.247 < 0.001
Liver cirrhosis 0   
No portal hypertension − 0.477 0.174 0.008
Portal hypertension 0   
APACHE III admission diagnosis
 Cardiovascular 0.678 0.272 0.02
 Gastrointestinal 0.186 0.125 0.14
 Hematological 0.091 0.696 0.90
 Musculoskeletal − 0.286 0.365 0.44
 Renal 2.399 0.317 < 0.001
 Respiratory 0.086 0.111 0.44
 Sepsis 0   
  1. Adjusted for admission diagnosis, hospital site, baseline NEq/MAP ratio, continuous renal replacement therapy, age, administration of hydrocortisone, and presence of liver cirrhosis
  2. APACHE Acute Physiology And Chronic Health Evaluation, CRRT continuous renal replacement therapy, MAP mean arterial pressure, NEq noradrenaline equivalents, NEq/MAP noradrenaline equivalents to MAP ratio (a higher ratio indicates higher vasopressor need to maintain a certain MAP)